Susan G. Arbuck

53.0k total citations · 3 hit papers
88 papers, 40.5k citations indexed

About

Susan G. Arbuck is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Susan G. Arbuck has authored 88 papers receiving a total of 40.5k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 26 papers in Molecular Biology and 14 papers in Epidemiology. Recurrent topics in Susan G. Arbuck's work include Cancer Treatment and Pharmacology (29 papers), Cancer therapeutics and mechanisms (23 papers) and Colorectal Cancer Treatments and Studies (17 papers). Susan G. Arbuck is often cited by papers focused on Cancer Treatment and Pharmacology (29 papers), Cancer therapeutics and mechanisms (23 papers) and Colorectal Cancer Treatments and Studies (17 papers). Susan G. Arbuck collaborates with scholars based in United States, Malaysia and Ukraine. Susan G. Arbuck's co-authors include Larry Rubinstein, Richard Kaplan, Michaele C. Christian, Janet Dancey, P. Therasse, Lalitha Shankar, Denis Lacombe, E. Eisenhauer, Stephen J. Gwyther and Margaret Mooney and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Susan G. Arbuck

87 papers receiving 39.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2008 20.7k citations E. Eisenhauer, P. Therasse et al. European Journal of Cancer profile →
New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 13.6k citations Patrick Therasse, Susan G. Arbuck et al. JNCI Journal of the National Cancer Institute profile →
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

2001 621 citations Larry Rubinstein, Michaele C. Christian et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan G. Arbuck United States	41	21.8k	16.5k	7.9k	6.9k	6.4k	88	40.5k
Richard Kaplan United Kingdom	48	22.4k 1.0×	20.2k 1.2×	7.3k 0.9×	7.8k 1.1×	7.5k 1.2×	173	46.0k
Larry Rubinstein United States	54	22.4k 1.0×	20.2k 1.2×	9.1k 1.2×	7.3k 1.1×	7.4k 1.2×	196	47.6k
Janet Dancey United States	68	19.9k 0.9×	15.4k 0.9×	8.6k 1.1×	5.5k 0.8×	5.4k 0.9×	205	38.3k
Elizabeth A. Eisenhauer Canada	61	15.2k 0.7×	12.7k 0.8×	12.0k 1.5×	4.1k 0.6×	5.4k 0.9×	213	41.9k
John D. Hainsworth United States	82	21.5k 1.0×	12.3k 0.7×	10.1k 1.3×	5.3k 0.8×	3.2k 0.5×	631	37.1k
Denis Lacombe Belgium	34	15.2k 0.7×	14.2k 0.9×	9.2k 1.2×	4.7k 0.7×	7.1k 1.1×	113	41.0k
Jan Bogaerts Belgium	39	16.2k 0.7×	12.0k 0.7×	4.5k 0.6×	5.3k 0.8×	5.2k 0.8×	114	30.1k
M. van Glabbeke Belgium	65	15.5k 0.7×	18.4k 1.1×	4.5k 0.6×	9.7k 1.4×	3.3k 0.5×	198	36.0k
Lalitha Shankar United States	27	13.7k 0.6×	11.4k 0.7×	3.5k 0.4×	4.8k 0.7×	6.2k 1.0×	84	27.0k
Daniel J. Sargent United States	89	37.1k 1.7×	17.9k 1.1×	7.1k 0.9×	12.3k 1.8×	5.5k 0.9×	477	57.7k

Countries citing papers authored by Susan G. Arbuck

Since Specialization

Citations

This map shows the geographic impact of Susan G. Arbuck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan G. Arbuck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan G. Arbuck more than expected).

Fields of papers citing papers by Susan G. Arbuck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan G. Arbuck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan G. Arbuck. The network helps show where Susan G. Arbuck may publish in the future.

Co-authorship network of co-authors of Susan G. Arbuck

This figure shows the co-authorship network connecting the top 25 collaborators of Susan G. Arbuck. A scholar is included among the top collaborators of Susan G. Arbuck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan G. Arbuck. Susan G. Arbuck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moulder, Stacy L., Frankie A. Holmes, Anthony W. Tolcher, et al.. (2010). A randomized phase 2 trial comparing 3‐hour versus 96‐hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 116(4). 814–821. 19 indexed citations

Eisenhauer, E., P. Therasse, Jan Bogaerts, et al.. (2008). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 45(2). 228–247. 20737 indexed citations breakdown →

Therasse, Patrick, Susan G. Arbuck, Elizabeth A. Eisenhauer, et al.. (2005). New guidelines to evaluate the response to treatment in solid tumors. Breast Cancer. 12(S1). S16–S27. 476 indexed citations

Argiris, Athanassios, Peter Heald, Timothy M. Kuzel, et al.. (2001). Phase II Trial of 9-Aminocamptothecin as a 72-h Infusion in Cutaneous T-Cell Lymphoma. Investigational New Drugs. 19(4). 321–326. 9 indexed citations

Korn, Edward L., Susan G. Arbuck, James M. Pluda, et al.. (2001). Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?. Journal of Clinical Oncology. 19(1). 265–272. 214 indexed citations

Therasse, Patrick, Susan G. Arbuck, Elizabeth A. Eisenhauer, et al.. (2000). New Guidelines to Evaluate the Response to Treatment in Solid Tumors. JNCI Journal of the National Cancer Institute. 92(3). 205–216. 13583 indexed citations breakdown →

Senderowicz, Adrian M., Donna Headlee, Sherman F. Stinson, et al.. (1998). Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.. Journal of Clinical Oncology. 16(9). 2986–2999. 338 indexed citations

Kudelka, Andrzej P., Rodger J. Winn, Creighton L. Edwards, et al.. (1997). An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-Cancer Drugs. 8(7). 657–661. 47 indexed citations

Simon, Richard, Larry Rubinstein, Susan G. Arbuck, et al.. (1997). Accelerated Titration Designs for Phase I Clinical Trials in Oncology. JNCI Journal of the National Cancer Institute. 89(15). 1138–1147. 433 indexed citations

10.

Höchster, Howard S., et al.. (1997). Phase I study of paclitaxel (P) combined with 14-day topotecan (T) Continuous IV (CIV) infusion in previously treated and untreated patients (PTS). European Journal of Cancer. 33. S250–S250. 4 indexed citations

11.

Beran, Miloslav, Hagop M. Kantarjian, S O'Brien, et al.. (1996). Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 88(7). 2473–2479. 103 indexed citations

12.

Arbuck, Susan G.. (1996). Workshop on phase I study design. Annals of Oncology. 7(6). 567–573. 48 indexed citations

13.

Arbuck, Susan G., Andrew Dorr, & Michael Friedman. (1994). Paclitaxel (Taxol) in Breast Cancer. Hematology/Oncology Clinics of North America. 8(1). 121–140. 35 indexed citations

14.

Fleming, Ronald A., Susan G. Arbuck, & Clinton F. Stewart. (1991). Interspecies differences in in vitro etoposide plasma protein binding. Biochemical Pharmacology. 42(11). 2246–2249. 14 indexed citations

15.

Bernstein, Zale P., Louis Vaickus, Neil Friedman, et al.. (1991). Interleukin-2 Lymphokine-Activated Killer Cell Therapy of Non-Hodgkinʼs Lymphoma and Hodgkinʼs Disease. Journal of Immunotherapy. 10(2). 141–146. 23 indexed citations

16.

Stewart, Clinton F., Susan G. Arbuck, Ronald A. Fleming, & William E. Evans. (1991). Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clinical Pharmacology & Therapeutics. 50(4). 385–393. 76 indexed citations

17.

Bernstein, Zale P., Louis Vaickus, Remedios Penetrante, et al.. (1991). Unusual Gastrointestinal Complications of Interleukin-2 Therapy. Journal of Immunotherapy. 10(3). 221–225. 9 indexed citations

18.

Arbuck, Susan G., et al.. (1990). A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. Cancer. 65(11). 2442–2445. 10 indexed citations

19.

Stewart, Clinton F., John A. Pieper, Susan G. Arbuck, & William E. Evans. (1989). Altered protein binding of etoposide in patients with cancer. Clinical Pharmacology & Therapeutics. 45(1). 49–55. 67 indexed citations

20.

Arbuck, Susan G., et al.. (1988). Progress Report on Studies of FAM-CF for Gastric Cancer and Intraperitoneal Administration of FUra-CF Followed by Cisplatin (DDP). Advances in experimental medicine and biology. 244. 285–293. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact